loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Ipca Laboratories Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Ipca Laboratories Ltd. 13 Aug 2026 13:46 PM

Q1FY27 Quarterly Result Announced for Ipca Laboratories Ltd.

Pharmaceuticals company Ipca Laboratories announced Q1FY27 results

Standalone Financial Highlights:

  • Total Income for Q1FY27 stood at Rs 2,136.66 crore, representing a YoY increase of 20.58% compared to Rs 1,771.92 crore in Q1FY26 and a QoQ increase of 15.86% from Rs 1,844.23 crore in Q4FY26.
  • Revenue from Operations reached Rs 2,119.24 crore in Q1FY27, up 21.31% YoY from Rs 1,746.90 crore in Q1FY26 and up 16.80% QoQ from Rs 1,814.35 crore in Q4FY26.
  • Profit Before Tax (PBT) for Q1FY27 was Rs 515.41 crore, showing a YoY growth of 44.47% compared to Rs 356.75 crore in Q1FY26 and a QoQ growth of 47.32% from Rs 349.85 crore in Q4FY26.
  • Net Profit after tax for the quarter was reported at Rs 373.29 crore in Q1FY27, growing by 42.46% YoY from Rs 262.04 crore in Q1FY26 and 42.32% QoQ from Rs 262.29 crore in Q4FY26.
  • EBITDA margin (before forex gain/loss and other income) improved to 26.27% in Q1FY27 compared to 23.82% in Q1FY26.
  • Other Income was Rs 17.42 crore in Q1FY27, a decrease of 30.38% YoY from Rs 25.02 crore in Q1FY26.
  • Basic Earnings Per Share (EPS) stood at Rs 14.71 for Q1FY27, compared to Rs 10.33 in Q1FY26 and Rs 10.34 in Q4FY26.

Consolidated Financial Highlights:

  • Total Income for Q1FY27 was Rs 2,813.36 crore, reflecting a YoY growth of 20.15% from Rs 2,341.51 crore in Q1FY26 and a QoQ growth of 13.34% from Rs 2,482.22 crore in Q4FY26.
  • Revenue from Operations grew by 20.76% YoY to Rs 2,788.10 crore in Q1FY27, compared to Rs 2,308.85 crore in Q1FY26. It also increased by 16.73% QoQ from Rs 2,388.48 crore in Q4FY26.
  • Profit Before Tax (PBT) for the quarter stood at Rs 572.08 crore in Q1FY27, up 73.09% YoY from Rs 330.51 crore in Q1FY26 and up 41.45% QoQ from Rs 404.45 crore in Q4FY26.
  • Net Profit attributable to owners of the parent was reported at Rs 401.89 crore in Q1FY27, a growth of 72.33% YoY compared to Rs 233.21 crore in Q1FY26 and a growth of 34.38% QoQ from Rs 299.07 crore in Q4FY26.
  • EBITDA margin (before forex gain/loss and other income) for Q1FY27 was 22.88%, compared to 18.39% in Q1FY26.
  • Other Income was Rs 25.26 crore in Q1FY27, representing a YoY decrease of 22.66% from Rs 32.66 crore in Q1FY26.
  • Basic Earnings Per Share (EPS) for Q1FY27 stood at Rs 15.84, against Rs 9.19 in Q1FY26 and Rs 13.31 in Q4FY26.

Business Highlights:

  • Revenue Break-up by Products:
    • Formulations: Total formulations revenue grew by 19% YoY to Rs 1,685.16 crore in Q1FY27. Domestic formulations contributed Rs 1,082.12 crore (up 13% YoY), while exports were Rs 603.04 crore (comprising Branded at Rs 143.27 crore, up 16% YoY; Institutional at Rs 119.75 crore, up 107% YoY; and Generics at Rs 340.02 crore, up 27% YoY).
    • APIs: Total APIs revenue stood at Rs 423.72 crore in Q1FY27, marking a growth of 30% YoY. Domestic API sales were Rs 91.37 crore (up 20% YoY) and Export API sales were Rs 332.35 crore (up 33% YoY).
  • Geographic Performance:
    • Revenue from India was Rs 1,229.21 crore in Q1FY27, compared to Rs 1,083.17 crore in Q1FY26.
    • Revenue from Outside India was Rs 1,558.89 crore in Q1FY27, compared to Rs 1,225.68 crore in Q1FY26.
  • Other Developments: The Board of Directors, in their meeting held on June 26, 2026, resolved to amalgamate M/s. Krebs Biochemicals & Industries Ltd. with the company, with an appointed date of April 1, 2026. However, no effect for this amalgamation has been given in the unaudited financial results pending necessary consents/approvals.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Total Income: Consolidated total income for Q4FY26 was Rs 2,482.22 crore, an increase of 2.88% QoQ from Rs 2,412.69 crore in Q3FY26 and an increase of 9.23% YoY from Rs 2,272.51 crore in Q4FY25. For the full year FY26, consolidated total income was Rs 9,820.78 crore, up 8.73% from Rs 9,032.39 crore in FY25.
  • Revenue from Operations: Consolidated revenue for Q4FY26 stood at Rs 2,388.48 crore, which was largely flat QoQ (-0.17%) compared to Rs 2,392.50 crore in Q3FY26, and grew 6.31% YoY from Rs 2,246.69 crore in Q4FY25. Annual consolidated revenue for FY26 reached Rs 9,646.33 crore against Rs 8,939.59 crore in FY25.
  • Net Profit (Attributable to Owners): Consolidated Net Profit for Q4FY26 was Rs 299.07 crore, down 8.34% QoQ from Rs 326.27 crore in Q3FY26 but up 340.98% YoY from Rs 67.82 crore in Q4FY25. For the full year FY26, consolidated Net Profit grew by 54.69% to Rs 1,141.12 crore from Rs 737.68 crore in FY25.
  • EBITDA: Consolidated EBITDA (before forex gain/loss, other income, and exceptional items) for Q4FY26 was Rs 490.21 crore, up 20% YoY from Rs 409.74 crore in Q4FY25. For FY26, EBITDA grew 18% to Rs 1,998.96 crore from Rs 1,693.13 crore in FY25.
  • Earnings Per Share (EPS): Consolidated basic EPS for Q4FY26 was Rs 11.79. For the full year FY26, it was Rs 44.98 compared to Rs 29.08 in FY25.

Standalone Financial Highlights:

  • Total Income: For Q4FY26, standalone total income stood at Rs 1,844.23 crore, representing a decrease of 1.01% QoQ compared to Rs 1,863.00 crore in Q3FY26, and an increase of 11.10% YoY from Rs 1,659.93 crore in Q4FY25. For the full year FY26, total income reached Rs 7,431.39 crore, up 10.11% from Rs 6,749.21 crore in FY25.
  • Revenue from Operations: In Q4FY26, standalone revenue was Rs 1,814.35 crore, down 1.67% QoQ from Rs 1,845.18 crore in Q3FY26 and up 10.74% YoY from Rs 1,638.44 crore in Q4FY25. Annual revenue for FY26 stood at Rs 7,336.75 crore compared to Rs 6,677.92 crore in FY25.
  • Net Profit: The standalone Net Profit for Q4FY26 was Rs 262.29 crore, a decline of 13.56% QoQ from Rs 303.45 crore in Q3FY26, but showing a significant recovery compared to a loss of Rs 65.05 crore in Q4FY25. For the full year FY26, Net Profit grew by 74.03% to Rs 1,132.52 crore from Rs 650.76 crore in FY25.
  • Earnings Per Share (EPS): Basic EPS for Q4FY26 was Rs 10.34. For the full year FY26, basic EPS stood at Rs 44.64 compared to Rs 25.65 in FY25.

Business Highlights

  • Segment Performance: The group operates in a single reportable segment, namely "Pharmaceuticals".
  • Geographic Performance (Q4FY26):
    • Indian Formulations: Income grew by 12% YoY to Rs 853.33 crore.
    • Exports Income: Total export formulations and APIs grew by 9% YoY to Rs 845.53 crore. Branded formulations exports grew by 14% to Rs 190.17 crore, while Generics formulations exports surged 39% to Rs 341.02 crore.
  • Yearly Revenue Break-up (FY26):
    • Domestic Formulations: Rs 3,817.24 crore, up 10% YoY.
    • Export Formulations: Rs 2,082.58 crore, up 10% YoY.
    • Export APIs: Rs 1,046.85 crore, up 18% YoY.
  • Dividend: The Board has recommended a dividend of Rs 6/- per share of Re 1/- each (600%) for the financial year ended March 31, 2026.
  • Exceptional Items: For FY26, the company recorded an exceptional charge of Rs 45.82 crore (Consolidated) and Rs 30.42 crore (Standalone) related to the "Impact of new Labour Codes" due to revised pay structures and enhanced employee benefits.
  • Subsidiary Developments: During the year, the company acquired a 100% equity interest in Unichem Laboratories Limited, Ireland, and incorporated a wholly-owned subsidiary in Germany.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q3FY26 results

Consolidated Financial Highlights:

  • Consolidated Net total Income up 7% at Rs 2,412.69 crore.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.15% in Q3FY26 as against @ 19.87% in Q3FY25.
  • Consolidated Net Profit at Rs 326.27 crore (after exceptional items) up 31%.
  • Exports Income up 13% at Rs 770.49 crore.

Standalone Financial Highlights:

  • Standalone Net total Income up 11% at Rs 1,863.00 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 26.09% in Q3FY26 as against @ 24.25% in Q3FY25.
  • Standalone Net Profit at Rs 303.45 crore (after exceptional items) up 13%.
  • Indian formulations income up 12% at Rs 984.00 crore.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q2FY26 results

  • Consolidated Net total Income up 9% at Rs 2,584.36 crore.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 21.68% in Q2FY26 as against @ 19.10% in Q2FY25.
  • Consolidated Net Profit at Rs 282.57 crore (after exceptional items) up 23%.
  • Exports Income up 7% at Rs 813.65 crore.
  • Indian formulations income up 8% at Rs 1018.90 crore.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q1FY26 results

  • Revenue from Operations: Rs 2,308.85 crore compared to Rs 2,092.63 crore during Q1FY25, a change of 10%.
  • EBITDA: Rs 424.58 crore compared to Rs 387.49 crore during Q1FY25, change 10%.
  • PBT: Rs 234.42 crore compared to Rs 198.98 crore during Q1FY25, change 18%.
  • PAT: Rs 233.21 crore compared to Rs 192.24 crore during Q1FY25, change 21%.
  • EPS: Rs 9.19 for Q1FY26.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Standalone Net total Income up 9% at Rs 1,659.93 crore.
  • Consolidated Net total Income up 11% at Rs 2,272.51 crore.
  • Indian formulations income up 11% at Rs 764.05 crore.
  • Exports Income up 6% at Rs 774.29 crore. • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 21.19% in Q4FY25 as against @ 18.50% in Q4FY24.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 18.24 % in Q4FY25 as against @ 14.98 % in Q4FY24.
  • Standalone Net Profit at Rs 216.49 crore (before exceptional items) up 36%.
  • Consolidated Net Profit at Rs 270.83 crore (before exceptional items) up 94%.
  • The Board has recommended a final dividend of Rs 2/- per share (200%).

FY25 Financial Highlights:

  • Standalone Net Total Income up 8% at Rs 6,749.21 crore.
  • Consolidated Net Total Income up 15% at Rs 9,032.39 crore.
  • Indian formulations income up 12% at Rs 3,455.10 crore.
  • Exports Income up 4% at Rs 2,808.96 crore.
  • Standalone EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 22.66% in FY25 as against @ 19.29 % in FY24.
  • Consolidated EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 18.94% in FY25 as against @ 16.72% in FY24.
  • Standalone Net Profit at Rs 932.30 crore (before exceptional items) up 40%.
  • Consolidated Net Profit at Rs 992.58 crore (before exceptional items) up 56%.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q3FY25 results

  • Standalone Net total Income up 10% at Rs 1,680.09 crore.
  • Consolidated Net total Income up 9% at Rs 2,265.48 crore.
  • Indian formulations income up 13% at Rs 877.17crore.
  • Exports Income up 6% at Rs 680.91 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 24.25% in Q3FY25 as against @ 18.52% in Q3FY24.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 19.87% in Q3FY25 as against @ 16.10% in Q3FY24.
  • Standalone Net Profit at Rs 267.56 crore (after exceptional items) up 95%.
  • Consolidated Net Profit at Rs 248.14 crore (after exceptional items) up 38%.

Result PDF

Pharmaceuticals company Ipca Laboratories announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Standalone Net total Income up 8% at Rs 1827.94 crore.
  • Consolidated Net total Income up 15% at Rs 2381.16 crore.
  • Indian formulations income up 11% at Rs 940.51 crore.
  • Exports Income up 6% at Rs 762.90 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.89% in Q2FY25 as against @ 20.86% in Q2FY24.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) . @1.9.10% in Q2FY25 as against@ 17.64 % in Q2FY24.
  • Standalone Net Profit at Rs 244.12 crore (after exceptional items) up 51%.
  • Consolidated Net Profit at Rs 229.48 crore (after exceptional items) up 58%.
  • The Board has declared an interim dividend of Rs 2/- per share (200%).

H1FY25 Financial Highlights:

  • Standalone Net Total Income up 6% at Rs 3409.19 crore.
  • Consolidated Net Total Income up 21% at Rs 4494.40 crore.
  • Indian formulations income up 11 % at Rs 1813.88 crore.
  • Exports Income up 1 % at Rs 1353.76 crore.
  • Standalone EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 22.59 % in FY25 as against @ 20.04 % in FY24.
  • Consolidated EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 18.83% in FY25 as against @ 18.05% in FY24.
  • Standalone Net Profit at Rs 448.25 crore (after exceptional items) up 36%.
  • Consolidated Net Profit at Rs 421.72 crore (after exceptional items) up 37%.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q1FY25 results:

  • Standalone Net total Income up 3% at Rs 1,581.25 crore. 
  • Consolidated Net total Income up 30% at Rs 2,113.24 crore. 
  • Indian formulations income up 12% at Rs 873.37 crore.
  • Exports Income down 4% at Rs 590.86 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.25% in Q1FY25 as against @19.13% in Q1FY24. 
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 18.52 % in Q1FY25 as against @ 18.57 % in Q1FY24.
  • Standalone Net Profit at Rs 204.13 crore (after exceptional items) up 23%.
  • Consolidated Net Profit at Rs 192.24 crore (after exceptional items) up 18 %.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Standalone Net total Income up 6% at Rs 1,525.72 crore.
  • Consolidated Net total Income up 33% at Rs 2,051.93 crore.
  • Indian formulations income up 13% at Rs 689.83 crore.
  • Exports Income up 7% at Rs 731.38 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 18.50% in Q4 FY24 as against @ 11.75% in Q4 FY23.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items).@ 14.98% in Q4 FY24 as against @11.29% in Q4 FY23.
  • Standalone Net Profit at Rs 64.76 crore (after exceptional items) down 24%.
  • Consolidated Net Profit at Rs 59.59 crore (after exceptional items) down 22%.
  • The Board has recommended final dividend of Rs 2/- per share (200%)

FY24 Financial Highlights:

  • Standalone Net Total Income up 6% at Rs 6,111 crore.
  • Consolidated Net Total Income up 23% at Rs 7,829.81 crore.
  • Indian formulations income up 12% at Rs 3,097.16 crore.
  • Exports Income up 2% at Rs 2,707.70 crore.
  • Standalone EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 19.29% in FY24 as against @ 16.22% in FY23
  • Consolidated EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 16.72% in FY24 as against @ 15.35% in FY23
  • Standalone Net Profit at Rs 530.41 crore (after exceptional items) up 5%.
  • Consolidated Net Profit at Rs 547.35 crore (after exceptional items) up 16%

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app